InsiderTrades.com logo

Christian Henry Biography and Net Worth

Director of WAVE Life Sciences
  • Phone
  • Email
  • Website


Christian Henry is an executive with more than 20 years of experience in diverse roles focused on growing companies in the life sciences industry. Mr. Henry currently serves as the President and Chief Executive Officer, as well as a member of the board of directors, of Pacific Biosciences, a publicly traded life sciences company. Since 2016, Mr. Henry has also served on the board of directors of Ginkgo Bioworks, a publicly traded synthetic biology company. From 2005 through January 2017, Mr. Henry was a key member of the executive team at Illumina, Inc. where he served in several different roles including Chief Financial Officer, Chief Commercial Officer, and General Manager of the Life Sciences Business. During his time at Illumina, he helped guide the company to grow from less than $75 million in revenue to more than $2.2 billion. Prior to Illumina, Mr. Henry was Chief Financial Officer for Tickets.com, served as Vice President of Finance and Corporate Controller for Affymetrix, Inc., and held a similar position at Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.). Mr. Henry earned a BA in biochemistry and cell biology from the University of California, San Diego and an MBA from the University of California, Irvine.

What is Christian O. Henry's net worth?

The estimated net worth of Christian O. Henry is at least $225.89 thousand as of August 13th, 2025. Mr. Henry owns 29,645 shares of WAVE Life Sciences stock worth more than $225,895 as of December 5th. This net worth approximation does not reflect any other assets that Mr. Henry may own. Learn More about Christian O. Henry's net worth.

How do I contact Christian O. Henry?

The corporate mailing address for Mr. Henry and other WAVE Life Sciences executives is 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER, SINGAPORE U0, 018936. WAVE Life Sciences can also be reached via phone at (656) 236-3388 and via email at [email protected]. Learn More on Christian O. Henry's contact information.

Has Christian O. Henry been buying or selling shares of WAVE Life Sciences?

Christian O. Henry has not been actively trading shares of WAVE Life Sciences within the last three months. Most recently, Christian O. Henry sold 9,670 shares of the business's stock in a transaction on Wednesday, August 13th. The shares were sold at an average price of $8.81, for a transaction totalling $85,192.70. Following the completion of the sale, the director now directly owns 29,645 shares of the company's stock, valued at $261,172.45. Learn More on Christian O. Henry's trading history.

Who are WAVE Life Sciences' active insiders?

WAVE Life Sciences' insider roster includes Paul Bolno (CEO), Chris Francis (insider), Christian Henry (Director), Kyle Moran (CFO), Ken Takanashi (Director), and Gregory Verdine (Director). Learn More on WAVE Life Sciences' active insiders.

Are insiders buying or selling shares of WAVE Life Sciences?

In the last twelve months, insiders at the sold shares 8 times. They sold a total of 467,533 shares worth more than $4,461,142.90. The most recent insider tranaction occured on November, 13th when Director Adrian Rawcliffe sold 16,115 shares worth more than $109,420.85. Insiders at WAVE Life Sciences own 24.0% of the company. Learn More about insider trades at WAVE Life Sciences.

Information on this page was last updated on 11/13/2025.

Christian O. Henry Insider Trading History at WAVE Life Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/13/2025Sell9,670$8.81$85,192.7029,645View SEC Filing Icon  
3/20/2025Sell10,500$9.77$102,585.0016,115View SEC Filing Icon  
See Full Table

Christian O. Henry Buying and Selling Activity at WAVE Life Sciences

This chart shows Christian O Henry's buying and selling at WAVE Life Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

WAVE Life Sciences Company Overview

WAVE Life Sciences logo
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.
Read More

Today's Range

Now: $7.62
Low: $7.12
High: $7.68

50 Day Range

MA: $7.49
Low: $6.67
High: $9.04

2 Week Range

Now: $7.62
Low: $5.28
High: $15.72

Volume

2,519,503 shs

Average Volume

2,285,890 shs

Market Capitalization

$1.27 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A